Acute Myeloid Leukemia in First Remission: To Choose Transplantation or Not?STONE, Richard M.Journal of clinical oncology. 2013, Vol 31, Num 10, pp 1262-1266, issn 0732-183X, 5 p.Article

Postremission therapy in adults with acute myeloid leukemiaSTONE, Richard M.Seminars in hematology. 2001, Vol 38, Num 3, pp 17-23, issn 0037-1963, SUP6Article

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)GUPTA, Pankaj; MULKEY, Flora; LARSON, Richard A et al.Investigational new drugs. 2013, Vol 31, Num 5, pp 1311-1320, issn 0167-6997, 10 p.Article

Mutated BCR-ABL Generates Immunogenic T-cell Epitopes in CML PatientsCAI, Ann; KESKIN, Derin B; SIDNEY, John et al.Clinical cancer research (Print). 2012, Vol 18, Num 20, pp 5761-5772, issn 1078-0432, 12 p.Article

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3FISCHER, Thomas; STONE, Richard M; KLIMEK, Virginia M et al.Journal of clinical oncology. 2010, Vol 28, Num 28, pp 4339-4345, issn 0732-183X, 7 p.Article

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome : safety, pharmacokinetics, and pharmacodynamicsDEANGELO, Daniel J; STONE, Richard M; SHIHONG SHENG et al.Blood. 2006, Vol 108, Num 12, pp 3674-3681, issn 0006-4971, 8 p.Article

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignanciesWADLEIGH, Martha; DEANGELO, Daniel J; GRIFFIN, James D et al.Blood. 2005, Vol 105, Num 1, pp 22-30, issn 0006-4971, 9 p.Article

Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: Durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host diseaseDEANGELO, Daniel J; HOCHBERG, Ephraim P; SOIFFER, Robert J et al.Clinical cancer research. 2004, Vol 10, Num 15, pp 5065-5071, issn 1078-0432, 7 p.Article

CD6 + donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donorsSOIFFER, Robert J; WELLER, Edie; ANDERSON, Kenneth C et al.Journal of clinical oncology. 2001, Vol 19, Num 4, pp 1152-1159, issn 0732-183XArticle

Disparity in Perceptions of Disease Characteristics, Treatment Effectiveness, and Factors Influencing Treatment Adherence Between Physicians and Patients With Myelodysplastic SyndromesSTEENSMA, David P; KOMROKJI, Rami S; STONE, Richard M et al.Cancer. 2014, Vol 120, Num 11, pp 1670-1676, issn 0008-543X, 7 p.Article

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502ATTAR, Eyal C; JOHNSON, Jeffrey L; BLUM, William et al.Journal of clinical oncology. 2013, Vol 31, Num 7, pp 923-929, issn 0732-183X, 7 p.Article

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710POWELL, Bayard L; MOSER, Barry; COUBAN, Stephen et al.Blood. 2010, Vol 116, Num 19, pp 3751-3757, issn 0006-4971, 7 p.Article

Treatment of Myelodysplastic Syndrome With 2 Schedules and Doses of Oral Topotecan : A Randomized Phase 2 Trial by the Cancer and Leukemia Group B (CALGB 19803)GRINBLATT, David L; DAOHAI YU; LARSON, Richard A et al.Cancer. 2009, Vol 115, Num 1, pp 84-93, issn 0008-543X, 10 p.Article

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemiaRAPONI, Mitch; LANCET, Jeffrey E; WRIGHT, John J et al.Blood. 2008, Vol 111, Num 5, pp 2589-2596, issn 0006-4971, 8 p.Article

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412STONE, Richard M; DEANGELO, Daniel J; FOX, Edward A et al.Blood. 2005, Vol 105, Num 1, pp 54-60, issn 0006-4971, 7 p.Article

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AMLJINGRUI JIANG; GUILLERMO PAEZ, J; FOX, Edward A et al.Blood. 2004, Vol 104, Num 6, pp 1855-1858, issn 0006-4971, 4 p.Article

United states multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemiaSOIGNET, Steven L; FRANKEL, Stanley R; SIEVERS, Eric L et al.Journal of clinical oncology. 2001, Vol 19, Num 18, pp 3852-3860, issn 0732-183XArticle

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A TrialAPPERLEY, Jane F; CORTES, Jorge E; DE SOUZA, Carmino A et al.Journal of clinical oncology. 2009, Vol 27, Num 21, pp 3472-3479, issn 0732-183X, 8 p.Article

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)BORRELLO, Ivan M; LEVITSKY, Hyam I; MASLYAR, Daniel J et al.Blood. 2009, Vol 114, Num 9, pp 1736-1745, issn 0006-4971, 10 p.Article

Recurrent Acute Promyelocytic Leukemia Presenting As a Sacral Nerve Root MassKESARI, Santosh; DRAPPATZ, Jan; AKAR, Serra et al.Journal of clinical oncology. 2008, Vol 26, Num 19, pp 3279-3281, issn 0732-183X, 3 p.Article

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaCHESON, Bruce D; GREENBERG, Peter L; MITTELMAN, Moshe et al.Blood. 2006, Vol 108, Num 2, pp 419-425, issn 0006-4971, 7 p.Article

Fifty years of clinical research by the leukemia committee of the cancer and leukemia Group BLARSON, Richard A; STONE, Richard M; MAYER, Robert J et al.Clinical cancer research. 2006, Vol 12, Num 11, issn 1078-0432, 3556s-3563s, 2Article

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A cancer and leukemia group B studyFARAG, Sherif S; RUPPERT, Amy S; STAMBERG, Judith et al.Journal of clinical oncology. 2005, Vol 23, Num 3, pp 482-493, issn 0732-183X, 12 p.Article

Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndromeSTONE, Richard M; GILLILAND, D. Gary; KLION, Amy D et al.Seminars in oncology. 2004, Vol 31, Num 2, pp 12-17, issn 0093-7754, 6 p., SUP6Article

Page / 3